Cognition Therapeutics Bolsa (NASDAQ: CGTX)

Últimas noticias sobre Cognition Therapeutics (NASDAQ:CGTX) Bolsa

Cognition Therapeutics

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics Inc

News

ZURA

Zura Bio Announces Submission Of Protocol To FDA For Phase 2 Study Of Tibulizumab In Adults With Systemic Sclerosis

Offerings

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Files For Offer And Resale By Selling Stockholders Of Up To 1,577,829 Shares Of Common Stock

Q4 2024 Guidance
<ul>
<li>Net Sales are expected to range between $13.5 - $14.0 million</li>
<li>Gross Margin is expected to be in the range of 22.0% - 25.0%</li>
<li>Operating Expenses are expected to be in a range of $(5.5) - $(6.5) million</li>
</ul>

Guidance

DFLI

Dragonfly Energy Sees Q4 2024 Net Sales $13.5M-$14M

Trading Ideas

CTRI

13F Shows Carl Icahn Added Stake In Centuri Holdings With 1,000,000 Shares

The company has entered into a securities purchase agreement with certain new and existing institutional investors for the purchase of an aggregate of&nbsp;17.50 million common shares of the Company, without par value, and accompanying Class B warrants to purchase up to an aggregate of 8.75 million Common Shares in a registered direct offering.&nbsp;

The Metals Company Plans $17.5M Direct Offering Of Common Shares And Class B Warrants

Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.79) by 49.37 percent. The company reported quarterly sales of $3.860 million which missed the analyst consensus estimate of $4.061 million by 4.95 percent. This is a 16.93 percent increase over sales of $3.301 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

VVOS

Vivos Therapeutics Q3 2024 GAAP EPS $(0.40) Beats $(0.79) Estimate, Sales $3.860M Miss $4.061M Estimate

OMNIQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMQS#NASDAQ">OMQS</a>) reported quarterly losses of $(0.15) per share. This is a 72.73 percent increase over losses of $(0.55) per share from the same period last year. The company reported $18.55 million in sales this quarter. This is a 7.57 percent increase over sales of $17.24 million the same period last year.

OMQS

OMNIQ Q3 EPS $(0.15) Up From $(0.55) YoY, Sales $18.55M Up From $17.24M YoY

Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. The company reported quarterly sales of $2.612 million which beat the analyst consensus estimate of $1.240 million by 110.56 percent. This is a 214.32 percent increase over sales of $831.000 thousand the same period last year.

OMGA

Omega Therapeutics Q3 2024 GAAP EPS $(0.30) Misses $(0.28) Estimate, Sales $2.612M Beat $1.240M Estimate

Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.18) by 38.89 percent. The company reported quarterly sales of $12.72 million which missed the analyst consensus estimate of $14.15 million by 10.09 percent. This is a 19.94 percent decrease over sales of $15.89 million the same period last year.

Dragonfly Energy Hldgs Q3 2024 GAAP EPS $(0.11) Beats $(0.18) Estimate, Sales $12.72M Miss $14.15M Estimate

Management

Omega Therapeutics Appoints Kaan Certel As CEO; Succeeds Mahesh Karande

WIIM

RSLS

ReShape Lifesciences shares are trading lower. The company reported Q3 financial results.

HALO

Halozyme Confirms Proposal To Combine With Evotec For €11/Share All-Cash Transaction

Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#NYSE">BABAF</a>) will be unveiling its second-quarter earnings on Friday, <a href="https://www.benzinga.com/quote/BABA/earnings">before market hours</a>. Wall Street is expecting $2.10 in EPS and $33.95 billion in revenue, per <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data.
This comes as the Chinese e-commerce giant faces mounting competition from rivals like JD.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) and Pinduoduo Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), as well as a challenging macroeconomic environment that has tempered consumer spending in China.
Still, some analysts are optimistic that Alibaba&#8217;s growing international digital commerce and cloud segments could drive meaningful results, particularly as the company looks to diversify its revenue sources beyond the domestic market.
With Alibaba's core and cloud divisions in focus, investors hope for upbeat numbers amid a challenging economic climate in China.
<h2 class="wp-block-heading">Alibaba Chart Signals Hints At A Challenging Road Ahead</h2>
From a technical analysis perspective, Alibaba's stock currently reflects a bearish sentiment. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14125936/Screenshot-2024-11-14-at-11.14.05-PM.png" alt="" class="wp-image-648695" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14125936/Screenshot-2024-11-14-at-11.14.05-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14125936/Screenshot-2024-11-14-at-11.14.05-PM-300x218.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111424&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Read Also: <a href="https://www.benzinga.com/news/global/24/11/41889911/whats-going-on-with-china-based-stocks-alibaba-jd-com-pdd-holdings-baidu-nio">What&#8217;s Going On With China-Based Stocks Alibaba, JD.com, PDD Holdings, Baidu, Nio?</a>
Trading at $90.32, BABA stock sits below several key moving averages, including its five, 20 and 50-day exponential moving averages, suggesting a continuation of selling pressure in the near term. BABA stock trades below its eight-day Simple Moving Average (SMA) of $94.97 and its 20-day SMA of $97.39, reinforcing these bearish signals. 
The Moving Average Convergence/Divergence (MACD) reading of a negative 2.01 supports a downward trend, though the Relative Strength Index (RSI) of 36.61 hints that Alibaba stock could be in the oversold territory soon. 
This could offer a short-term relief rally, but the technical signals broadly imply caution leading into the earnings report.
<h2 class="wp-block-heading">Analyst Ratings, Price Targets Signal Optimism Despite Challenges</h2>
Despite the near-term technical indicators, analysts hold an overall positive outlook on Alibaba, with a consensus Buy rating. The average analyst price target of $120 suggests a <a href="https://www.benzinga.com/quote/BABA/analyst-ratings">potential upside of 32.86%</a> from current levels. 
The anticipated growth in Alibaba's cloud and international commerce could be the drivers that could help Alibaba navigate the current economic uncertainties.
In the broader context, Alibaba has shown resilience with a 20.83% gain year-to-date, although it has seen a 16.21% decline over the past month, reflecting investor caution ahead of the earnings. 
With the Chinese economy in flux and competitive pressures high, all eyes will be on Alibaba's guidance for the upcoming quarters. If Alibaba can deliver strong growth in its cloud and international businesses, it could signal a turnaround, potentially setting the stage for a stock price rebound. 
As Alibaba navigates these dynamics, Friday's earnings report will be pivotal in determining if this bullish narrative holds.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41902202/trumps-china-hawks-rumored-for-top-roles-yuan-hits-3-month-low">Chinese Currency Hits 3-Month Low: Trump&#8217;s Anti-China Cabinet Appointments Rattle Investors</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Alibaba Earnings Could Offer Clues On Challenging Climate: Why Bearish Signals Loom Over China Stock

Contracts

POCI

Precision Optics Secures Initial $340K Production Order From A Large, Global Medical Device Company For New Single-use Ophthalmic Endoscope

ETSY

LBRDA

MTCH

Elliott Investment Management 13F Shows Increased Put Position In Select Sector SPDR Energy ETF From 14,500,000 To 22,600,000 Shares; Increased Stake In Match Group By 3% From 11,705,013 To 12,054,832 Shares; Etsy By 11% From 4,500,000 To 5,000,000 Shares; Put Position In Ishares Russell 2000 ETF By 25% From 1,000,000 To 1,250,000 Shares; Liberty Broadband Corp By 9% From 2,192,858 To 2,384,481 Shares; Western Digital Corp By 90% From 1,185,000 Shares To 2,250,000 Shares

<ul>
<li>Established clinical proof-of-mechanism and validation of epigenomic controllers as potential new class of medicines from completed Phase 1 MYCHELANGELO&#x2122; I trial for c-MYC in HCC; Company exploring strategic partnership opportunities for Phase 2 development of OTX-2002 
<ul>
<li>Company is focusing capital resources on three prioritized programs that reflect Omega's unique value proposition to enable precision epigenomic control for potential therapeutic advantages versus existing modalities</li>
</ul>
</li>
</ul>

Biotech

General

Omega Therapeutics Completes Phase 1 MYCHELANGELO I Clinical Trial And A Strategic Prioritization Of Its Pipeline

Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.56) by 33.93 percent. This is a 63 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $1.46 million which beat the analyst consensus estimate of $1.14 million by 27.72 percent. This is a 17.42 percent increase over sales of $1.24 million the same period last year.

PSTV

Plus Therapeutics Q3 EPS $(0.37) Beats $(0.56) Estimate, Sales $1.46M Beat $1.14M Estimate

Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys.

Exagen Reports Validation, Regulatory Submission For Approval Of New Systemic Lupus Erythematosus And Rheumatoid Arthritis Biomarkers, To Be Incorporated Into AVISE CTD Platform

Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) reported its fourth-quarter results after Thursday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g41988497/applied-materials-announces-fourth-quarter-and-fiscal-year-2024-results">details from the report. </a>
The Details: Applied Materials reported quarterly earnings of $2.32 per share, which beat the analyst consensus estimate of $2.19. Quarterly revenue clocked in at $7.05 billion, which beat the analyst consensus estimate of $6.95 billion and is an increase over sales of $6.72 billion from the same period last year.
The company reported a gross margin of 47.5% and a record operating income of $2.06 billion or 29.3% of net revenue.
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
&#8220;Applied Materials&#8217; technology leadership and strong execution drove record Q4 and fiscal 2024 performance, our fifth consecutive year of growth,&#8221; said Gary Dickerson, president and CEO.
&#8220;Our portfolio of products and services uniquely positions us to enable our customers in their pursuit of AI and energy-efficient computing. As these key drivers of semiconductor innovation continue to grow in importance, the industry&#8217;s roadmap is becoming increasingly dependent on materials engineering, where Applied is the clear leader,&#8221; Dickerson added. 
Outlook:&nbsp;In the first quarter of fiscal 2025, Applied expects net revenue to be approximately $7.15 billion, plus or minus $400 million. Non-GAAP diluted EPS is expected to be approximately $2.29, plus or minus 18 cents. 
AMAT Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Applied Materials shares are down 3.84% after-hours at $178.87 at the time of publication Thursday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Movers

AMAT

Applied Materials Shares Slip Despite Better-Than-Expected Q4 Results

FLEX

Flex Acquires JetCool To Expand Data Center; Terms Not Disclosed

Cognition Therapeutics (CGTX) just unveiled an update. Cognition Therapeutics, Inc. has prepared a presentation for investors, analysts, and other ...

Cognition Therapeutics Shares Investor Presentation Update

Cognition Therapeutics ( ($CGTX) ) has shared an update. Cognition Therapeutics, Inc. is engaging investors with a presentation that outlines their...

Cognition Therapeutics Highlights CT1812 Potential in CNS Disorders

Warning: CGTX is at high risk of performing badly

Cognition Therapeutics (CGTX) has released a new Conversations video podcast episode. The new episode, which has been launched during DLB Awareness...

Cognition Therapeutics releases new episode of 'Conversations' podcast

Cognition Therapeutics (CGTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

Positive Buy Rating Reaffirmed for Cognition Therapeutics Amid Promising Alzheimer's Drug Data

Oppenheimer analyst Jay Olson maintained a Buy rating on Cognition Therapeutics (CGTX – Research Report) yesterday and set a price target of $9.00....

Cognition Therapeutics (CGTX) Gets a Buy from Oppenheimer

"In the third quarter and recent weeks Cognition Therapeutics (CGTX) achieved one of the most important milestones in its history as the Phase 2 SH...

Cognition Therapeutics reports Q3 EPS (25c), consensus (22c)

Cash and cash equivalents as of September 30, 2024 were approximately $22.0 million and total grant funds remaining from the NIA were $53.6 million...

Cognition Therapeutics sees cash runway into 2Q25

Cognition Therapeutics GAAP EPS of -$0.25

Cognition Therapeutics, Inc. ( ($CGTX) ) has released its Q3 earnings. Here is a breakdown of the information Cognition Therapeutics, Inc. presente...

Cognition Therapeutics Reports Promising Q3 2024 Results

CGTX

Health Care

Press Releases

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Comments

Cognition Therapeutics

Noticias

Últimas noticias sobre Cognition Therapeutics (NASDAQ:CGTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL